Philip Morris Q3 2026 Earnings: Record $11.4B Revenue as Reported EPS Falls to $2.12

On October 21, 2026, Philip Morris International reported third-quarter net revenues of $11.438 billion (+5.5%), gross profit of $7.854 billion (+6.7%) and operating income of $4.866 billion (+14.1%) — a new record quarterly high on all three, the release says — while reported diluted EPS fell 4.9% to $2.12 and adjusted diluted EPS hit its own record at $2.36 (+5.4%). The $0.24 gap between the two EPS numbers is this quarter in miniature: an operating machine at full tilt, with a GAAP bottom line held hostage by a non-cash fair-value swing. Beneath both sits the strangest balance sheet among large caps: negative $7.9 billion of book equity, $2 billion less negative than a year ago.

The Headline Numbers​

Every figure below comes from the condensed statements in Exhibit 99.2 to PMI's Form 8-K and the earnings release.

"Total revenue" is the line PMI calls net revenues — already net of the $50-billion-a-year excise taxes that never touch the income statement. "Net income" is net earnings attributable to PMI: consolidated net earnings of $3,522 million less $209 million for noncontrolling interests.

Operating leverage did the heavy lifting. Revenue grew 5.5% while marketing, administration and research costs — PMI's entire operating-expense line — actually fell 2.1% to $2,993 million, so operating income grew more than twice as fast as the top line. That is what a 42.5% operating margin looks like from the inside: pricing and mix drop straight through because the cost base barely moves.

Then the bottom half of the statement gave half of it back. The tax provision rose 31.3% to $986 million as the effective rate climbed from 18.7% to 21.5%, and the equity-investments line swung from $345 million of income to an $86 million loss — the fair-value adjustment the release blames for the reported-EPS decline. Nothing in that swing reflects selling fewer heated-tobacco units; it is mark-to-market noise on securities PMI holds, and it is the whole reason $2.12 and $2.36 describe the same quarter.

Revenue Deep Dive​

PMI now reports three commercial units — international smoke-free, international combustibles, and the U.S. — and the quarter belonged to the oldest one:

Combustibles delivered what the release calls "an exceptional quarter." Cigarette shipments were broadly flat — growth in Turkey, Indonesia and Egypt offsetting declines elsewhere — but net revenues grew 6.5% on "another impressive quarter of 8.9% pricing, partly offset by geographic mix." Marlboro gained half a point to a record 11.4% category share. One caveat travels with the number: the quarter "benefited from the favorable restructuring of distribution terms in certain markets, which is not expected to recur at the same level in future quarters." Some of that 8.9% is a one-time trade-terms gain wearing a pricing costume.

Smoke-free looks soft on shipments (+0.7% reported) and strong on offtake — the tension that defines this business. Reported revenue suffered from "a challenging HTU comparison due to the phasing of shipments between periods, notably in Japan," while adjusted in-market sales, "the closest proxy to consumer offtake," accelerated to 8.0% growth. IQOS heat sticks "grew shipment volumes by 1.5% to 41.5 billion units, at the high end of our previously disclosed expectations," with offtake up 7.1% — 10% excluding Japan and Poland — and category share at 9.9% of combined cigarette and stick volumes where present. Oral turned positive (+0.5%) as modern pouches grew 20.6%, and VEEV e-vapor shipments jumped 61.6% while "further reinforced its leadership position in Europe." Smoke-free passed 40% of quarterly revenue, sits at 42% year-to-date across 110 markets, and exceeds 50% in more than 30 of them. The ledger line to watch next quarter is whether IMS strength converts back into shipments once Japan's excise-driven pantry-loading washes out.

The U.S. is the growth story with an asterisk. Revenue surged 22.7% on ZYN shipments up 4.2% to 3.2 billion pouches plus favorable pricing against last year's promotions, and ZYN "increased its category share by over 100 basis points between June and September, as estimated by Nielsen." But operating companies income fell 3.3% (up just 1.5% organically, to $171 million) because PMI is pouring money into the portfolio expansion — ZYN ULTRA, new flavors, the 20-pouch can transition — and "we plan to further increase investments to support the brand in the fourth quarter." Revenue up 23%, profit flat: that is a land-grab P&L, and the FDA's August authorization of 11 more ZYN ULTRA variants (31 total, "more than any other nicotine brand on the market") is the moat being dug underneath it.

The Margin Story​

Four periods, three margins, one story — operations expanding, the tax and fair-value lines deciding what shareholders keep:

Gross margin has risen almost four points in two years on the two forces the release names: "strong combustible pricing, scale and SFP mix benefits." With cigarettes still 60% of revenue, 8.9% pricing on a flat volume base is pure margin — and smoke-free mix helps because heated tobacco and pouches carry no leaf cost. Operating margin jumped more than three points year-over-year, and the operating-expense ratio falling two points — revenue up while costs declined in absolute terms — contributed the bulk of it.

Net margin went the other way, from 32.1% to 29.0%, and the walk is mechanical rather than operational: the $431 million year-over-year swing in the equity-securities line did most of the damage, with the tax rate normalizing from an unusually low 18.7% toward the guided 21.5% adding most of the rest. Ignore FY2024's 18.6% net margin when drawing trend lines — that year carries the $2.3 billion RBH impairment, a labeled one-off in the ledger, without which the margin would have printed near 25%.

The One Big Question: Is the Real Number $2.12 or $2.36?​

When the story is GAAP versus non-GAAP, the bridge table is the story. Here is PMI's own reconciliation for the quarter:

Start with the fair-value line, because it explains the paradox. A year ago it was a $0.07 gain; this quarter it is a $0.06 loss — a $0.13-per-share swing on securities PMI neither bought nor sold. Add last year's one-offs that flattered neither number the same way (a $0.10 German excise litigation charge, a $0.09 wellness impairment, partly offset by $0.10 of RBH plan income and $0.14 of tax items), and reported EPS was always going to tell a noisier story than the business. The release is explicit: reported EPS fell "mainly due to the non-cash fair value adjustment for equity security investments."

The serious question is the $0.13 of amortization, because unlike the fair value it recurs every quarter — $0.50 per share guided for the full year, mostly the Swedish Match intangibles. Adding it back assumes acquired brands and customer relationships cost shareholders nothing, which is true in cash terms and false in economic terms: PMI paid real money for Swedish Match, and amortization is the receipt. The honest read is that neither number is the business alone: $2.36 overstates by the amortization that represents a real acquisition price, and $2.12 understates by mark-to-market noise. Nine-month figures frame it the same way — reported $5.48 down 7.0%, adjusted $6.52 up 11.8% — and the full-year guide (reported $7.11–$7.26, adjusted growth of 7.5–9.5% ex-currency off $7.54) asks investors to underwrite the adjusted number. The ledger below books the GAAP one: net earnings attributable to PMI of $3,313 million, the $2.12, with no adjustments and nowhere to hide them.

Tracking a $40 Billion Consumer Goods Company in Plain Text​

Double-entry bookkeeping forces every dollar to reconcile, which makes it the perfect antidote to adjusted earnings: this is the quarter exactly as filed, in the form we model every company. Income is negative (a credit), expenses positive — and the transaction sums to zero:

2026-09-30 balance Liabilities:NonCurrent:LongTermDebt         -41709 MUSD  ; long-term debt
2026-09-30 balance Equity:UndisaggregatedParent                  7937 MUSD  ; total PMI stockholders' deficit (7,937) — a deficit, so a debit balance (total stockholders' deficit (5,945))
2026-09-30 balance Equity:NoncontrollingInterests               -1992 MUSD  ; noncontrolling interests
; Check: −11,438 + 3,584 + 2,993 + −5 + 199 + 73 + 86 + 209 + 986 + 3,313 = 0 ✓
2026-09-30 * "Philip Morris International Inc." "FY2026Q3 Income Statement"
  Income:Revenue                             -11438 MUSD  ; net revenues
  Expenses:CostOfRevenue                       3584 MUSD  ; cost of sales
  Expenses:SellingGeneralAdministrative        2993 MUSD  ; marketing, administration and research costs
  Expenses:OtherNet                              -5 MUSD  ; corporate expenses and other — a net credit of 5 this quarter, inside operating income
  Expenses:OtherNet                             199 MUSD  ; interest expense, net
  Expenses:OtherNet                              73 MUSD  ; pension and other employee benefit costs
  Expenses:OtherNet                              86 MUSD  ; equity investments and securities loss, net
  Expenses:OtherNet                             209 MUSD  ; net earnings attributable to noncontrolling interests, added back as the filing does
  Expenses:IncomeTax                            986 MUSD  ; provision for income taxes
  Equity:Adjustments                           3313 MUSD  ; net earnings attributable to PMI offset (equity set by balance assertion)

The one balance-sheet number that tells the narrative is the deficit: PMI's book equity is negative $7.9 billion because $35.5 billion of treasury stock — decades of buybacks — outweighs paid-in capital plus reinvested earnings. That hole is filling at roughly $2 billion a year ($(11.8) billion at the end of 2024, $(10.0) billion at the end of 2025, $(7.9) billion now) because PMI earns far more than it pays out, and the debt stack is shrinking with it: total debt down to $47.6 billion, net debt to adjusted EBITDA down to 2.17x from 2.53x, with management targeting close to 2.0x by year-end. A negative-equity company deleveraging itself is only possible with margins like these.

The Multi-Year Arc​

Five years of the transition, with nine months of 2026 appended — revenue compounding near 9% while smoke-free marches from under a third of sales toward half:

(FY2022–FY2023 from the 10-K comparative columns; the ledger covers FY2024 onward.)

Two features stand out. First, the compounding is real and accelerating: revenue up 28% in three years, and 2025's $11.3 billion of net income finally surpassed the 2022 level after two years of impairments and tax noise. Second, the smoke-free share gains roughly two and a half points a year — 32.1% to 41.6% — which means the "smoke-free future" arrives by arithmetic, not by press release: at this pace combustibles become the minority of revenue around 2030. The bear case for the multiple is that the market already prices this; the bull case is that each point of mix shift carries higher gross margin with it, so earnings compound faster than revenue all the way there.

The Verdict: Bull vs. Bear​

Bull Case

• Record revenue, gross profit and operating income in the same quarter, with 42.5% operating margins and opex declining in absolute terms, is best-in-class execution by any standard.
• The offtake data (SFP IMS +8%, IQOS share 9.9% and rising, ZYN +100bp of category share in a quarter) says consumer demand is stronger than the shipment-phased revenue print.
• Pricing power is extraordinary: 8.9% on cigarettes with flat volumes and record Marlboro share means the installed base funds the transition indefinitely.
• Deleveraging is ahead of schedule (2.17x net debt/EBITDA vs. a ~2.0x year-end target) while the dividend just rose 8.8% to $6.40 annualized — cash returns plus balance-sheet repair at once.
• The adjusted-EPS guide (7.5–9.5% ex-currency growth) plus a sixth straight year of volume growth underwrites mid-teens earnings compounding if currency cooperates.

Bear Case

• None of management's signals mention demand exceeding supply or tight capacity — this is a pricing-and-mix story, and 8.9% cigarette pricing cannot compound forever against declining industry volumes.
• Part of the pricing beat is the distribution-terms restructuring that "is not expected to recur," so Q4 faces a tougher comparison than the headline run-rate implies.
• The U.S. land grab is expensive: revenue up 23% with profit flat, more investment promised for Q4, in a nicotine-pouch category where competitors are explicitly cited as a risk.
• The GAAP bottom line keeps disappointing optically (reported EPS −4.9% in Q3, −7.0% over nine months), and a market that screens on GAAP multiples may not pay for the adjusted number.
• Energy-cost inflation from Middle East tensions and Ukraine supply disruptions are called out as growing Q4 headwinds, with "a larger proportion of input price increases" still to take effect.

Our Take

Buy the machine, discount the multiple expansion. This is a company growing volumes six years running with 42% operating margins, converting the proceeds into deleveraging and a $6.40 annualized dividend that just rose 8.8% — the quality is not debatable. But the quarter's two genuine warts, the non-recurring trade-terms benefit inside combustibles and the heavy U.S. investment spend, both hit hardest in Q4, and the stock will likely need the full-year guide delivered cleanly — reported EPS in the $7.11–$7.26 range — before the GAAP discount closes. The ledger says the business is worth more than $2.12 a quarter; the market is right to ask PMI to prove it four quarters in a row.